These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 2210078)
1. Limited duration of remission of insulin dependency in children with recent overt type I diabetes treated with low-dose cyclosporin. Bougnères PF; Landais P; Boisson C; Carel JC; Frament N; Boitard C; Chaussain JL; Bach JF Diabetes; 1990 Oct; 39(10):1264-72. PubMed ID: 2210078 [TBL] [Abstract][Full Text] [Related]
2. Plasma C-peptide levels and clinical remissions in recent-onset type I diabetic patients treated with cyclosporin A and insulin. Assan R; Feutren G; Sirmai J; Laborie C; Boitard C; Vexiau P; Du Rostu H; Rodier M; Figoni M; Vague P Diabetes; 1990 Jul; 39(7):768-74. PubMed ID: 2191883 [TBL] [Abstract][Full Text] [Related]
3. Cyclosporin-induced remission of IDDM after early intervention. Association of 1 yr of cyclosporin treatment with enhanced insulin secretion. The Canadian-European Randomized Control Trial Group. Diabetes; 1988 Nov; 37(11):1574-82. PubMed ID: 2903105 [TBL] [Abstract][Full Text] [Related]
4. Metabolic and immunological effects of cyclosporin in recently diagnosed type 1 diabetes mellitus. Assan R; Feutren G; Debray-Sachs M; Quiniou-Debrie MC; Laborie C; Thomas G; Chatenoud L; Bach JF Lancet; 1985 Jan; 1(8420):67-71. PubMed ID: 2857024 [TBL] [Abstract][Full Text] [Related]
5. Lack of predictive value of islet cell antibodies, insulin antibodies, and HLA-DR phenotype for remission in cyclosporin-treated IDDM patients. The Canadian-European Randomized Control Trial Group. Mandrup-Poulsen T; Mølvig J; Andersen HU; Helqvist S; Spinas GA; Munck M Diabetes; 1990 Feb; 39(2):204-10. PubMed ID: 2227128 [TBL] [Abstract][Full Text] [Related]
6. Clinical trials of cyclosporin in IDDM. Dupré J; Stiller CR; Gent M; Donner A; von Graffenried B; Heinrichs D; Jenner M; Keown P; Mahon J; Martell R Diabetes Care; 1988; 11 Suppl 1():37-44. PubMed ID: 3069390 [TBL] [Abstract][Full Text] [Related]
7. Hypersensitivity to insulin during remissions in cyclosporin-treated IDDM patients. Burcelin RG; Eddouks M; Beylot M; Normand S; Boitard C; Feutren G; Landais P; Riou JP; Girard JR; Bach JF Diabetes Care; 1993 Jun; 16(6):881-8. PubMed ID: 8325202 [TBL] [Abstract][Full Text] [Related]
8. Long-term results of early cyclosporin therapy in juvenile IDDM. De Filippo G; Carel JC; Boitard C; Bougnères PF Diabetes; 1996 Jan; 45(1):101-4. PubMed ID: 8522052 [TBL] [Abstract][Full Text] [Related]
9. Natural course of remission in IDDM during 1st yr after diagnosis. Martin S; Pawlowski B; Greulich B; Ziegler AG; Mandrup-Poulsen T; Mahon J Diabetes Care; 1992 Jan; 15(1):66-74. PubMed ID: 1737543 [TBL] [Abstract][Full Text] [Related]
10. Proinsulin and C-peptide at onset and during 12 months cyclosporin treatment of type 1 (insulin-dependent) diabetes mellitus. Snorgaard O; Hartling SG; Binder C Diabetologia; 1990 Jan; 33(1):36-42. PubMed ID: 2303172 [TBL] [Abstract][Full Text] [Related]
11. Glutamic acid decarboxylase (GAD65) autoantibodies in prediction of beta-cell function and remission in recent-onset IDDM after cyclosporin treatment. The Canadian-European Randomized Control Trial Group. Petersen JS; Dyrberg T; Karlsen AE; Mølvig J; Michelsen B; Nerup J; Mandrup-Poulsen T Diabetes; 1994 Nov; 43(11):1291-6. PubMed ID: 7926302 [TBL] [Abstract][Full Text] [Related]
13. Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset. Stiller CR; Dupré J; Gent M; Jenner MR; Keown PA; Laupacis A; Martell R; Rodger NW; von Graffenried B; Wolfe BM Science; 1984 Mar; 223(4643):1362-7. PubMed ID: 6367043 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of insulin release in vitro mediated by mononuclear cells from diabetic patients treated with cyclosporin A or placebo. Debray-Sachs M; Sai P; Feutren G; Lang F; Maugendre D; Boitard C; Hors J; Bach JF Diabetes; 1988 Jul; 37(7):873-7. PubMed ID: 3290005 [TBL] [Abstract][Full Text] [Related]
15. Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Results of a multicentre double-blind trial. Feutren G; Papoz L; Assan R; Vialettes B; Karsenty G; Vexiau P; Du Rostu H; Rodier M; Sirmai J; Lallemand A Lancet; 1986 Jul; 2(8499):119-24. PubMed ID: 2873396 [TBL] [Abstract][Full Text] [Related]
16. Seven years of remission in a type I diabetic patient. Koivisto VA; Leirisalo-Repo M; Ebeling P; Tuominen JA; Knip M; Turunen U; Mandrup-Poulsen T; Pelkonen R Diabetes Care; 1993 Jul; 16(7):990-5. PubMed ID: 8359107 [TBL] [Abstract][Full Text] [Related]
17. Cyclosporin A does not delay insulin dependency in asymptomatic IDDM patients. Rakotoambinina B; Timsit J; Deschamps I; Laborde K; Jos J; Boitard C; Assan R; Robert JJ Diabetes Care; 1995 Nov; 18(11):1487-90. PubMed ID: 8722075 [TBL] [Abstract][Full Text] [Related]
18. [Use of cyclosporin A for remission induction in newly-detected insulin-dependent diabetes]. Zamaklar M; Lalić N; Djordjević P; Dragasević M; Vujosević S; Savić K; Kalimanovska V Glas Srp Akad Nauka Med; 1994; (44):89-100. PubMed ID: 7590419 [TBL] [Abstract][Full Text] [Related]